Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 11/20 | 0.50 |
| ▸ | MTOR | P42345 | 4/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598898 | 0.89 | PIK3CA (0.53) | PIK3CAPIK3CDATRMTORPRKDC | |
| SCHEMBL13336861 | 0.86 | PIK3CA (0.79) | PIK3CAPIK3CDATRMTORPRKDC | |
| SCHEMBL3606859 | 0.84 | ATR (0.52) | PIK3CAPIK3CDATRMTORPRKDC | |
| SCHEMBL13142276 | 0.82 | PIK3CD (0.60) | PIK3CAPIK3CDATRMTORPRKDC | |
| SCHEMBL13119579 | 0.81 | ATR (0.50) | PIK3CAPIK3CDATRMTORPRKDC | |
| SCHEMBL3612884 | 0.79 | PIK3CD (0.57) | PIK3CAPIK3CDATRMTORPRKDC | |
| SCHEMBL13406366 | 0.79 | PIK3CA (0.58) | PIK3CAPIK3CDATRMTORPRKDC | |
| SCHEMBL13220255 | 0.79 | PIK3CA (0.79) | PIK3CAPIK3CDATRMTOR | |
| SCHEMBL13119567 | 0.78 | PIK3CA (0.49) | PIK3CAPIK3CDATR | |
| SCHEMBL3600404 | 0.78 | PIK3CA (0.47) | PIK3CAATRMTORPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | claimed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | PIK3CA 1/4885PIK3CD 2/4885ATR 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.